Somatic mutations predict prognosis in myelodysplastic syndrome patients with normal karyotypes-Reference-Cited by-同舟云学术

Somatic mutations predict prognosis in myelodysplastic syndrome patients with normal karyotypes

Published:2021-07-26 Issue:1 Volume:6 Page:
ISSN:2059-3635
Container-title:Signal Transduction and Targeted Therapy
language:en
Short-container-title:Sig Transduct Target Ther

Author:

Zeng Xiangzong,Zhang Yu,Zhao Ke,Zhou Lingling,Zhou Ya,Xuan Li,Cao Rui,Xu Jun,Dai Min,Liu Qifa

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics

Link

http://www.nature.com/articles/s41392-021-00606-3.pdf

Reference5 articles.

1. Bejar, R. et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J. Clin. Oncol. 32, 2691–2698 (2014).

2. Yoshizato, T. et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. Blood 129, 2347–2358 (2017).

3. Liang, S. et al. Prognostic value of DNMT3A mutations in myelodysplastic syndromes: a meta-analysis. Hematology 24, 613–622 (2019).

4. Lin, S. C. et al. FAT1 somatic mutations in head and neck carcinoma are associated with tumor progression and survival. Carcinogenesis 39, 1320–1330 (2018).

5. Kim, R. et al. Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. 34, 1730–1740 (2020).

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms;Cancers;2024-04-19

2. Comparison of the Molecular International Prognostic Scoring System (IPSS-M) and Revised International Prognostic Scoring System (IPSS-R) in predicting the prognosis of patients with myelodysplastic neoplasms treated with decitabine;Oncologie;2024-01-18

3. ASSOCIATION BETWEEN LEUKEMIC EVOLUTION AND UNCOMMON CHROMOSOMAL ALTERATIONS IN PEDIATRIC MYELODYSPLASTIC SYNDROME;Mediterranean Journal of Hematology and Infectious Diseases;2024-01-01

4. Impact of IPSS-M implementation in real-life clinical practice;Frontiers in Oncology;2023-05-18

5. The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial;The Lancet Haematology;2023-03